PMN — ProMIS Neurosciences Share News
0.000.00%
Last trade - 00:00ProMIS Neurosciences Q2 net loss widens
ProMIS Neurosciences Inc expected to post a loss of $1.38 a share - Earnings Preview
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:09 AM
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Brief: Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial
Brief: Plasma pTau Identified as Key Early Endpoint in Alzheimer's Research
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Brief: ProMIS Neurosciences Files Prospectus Of 28.2 Mln Common Shares Offering Relates To Resale By Selling Securityholders
Brief: Promis Neurosciences Inc Files For Mixed Shelf Of Up To $50 Million – SEC Filing
ProMIS Neurosciences Inc reports results for the quarter ended June 30 - Earnings Summary
ProMIS Neurosciences Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: ProMIS Neurosciences Announces Private Placement Financing
ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings Summary